SABS
SAB Biotherapeutics Inc
NASDAQ: SABS · HEALTHCARE · BIOTECHNOLOGY
$3.74
+7.47% today
Updated 2026-04-30
Market cap
$248.07M
P/E ratio
—
P/S ratio
2.96x
EPS (TTM)
$-0.79
Dividend yield
—
52W range
$2 – $5
Volume
0.6M
SAB Biotherapeutics Inc (SABS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
15.00%
ROA
-28.20%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $3.44M | $-8.99M | 100.00% | -252.00% | -261.07% |
| 2020 | $55.24M | $20.12M | 100.00% | 37.22% | 36.42% |
| 2021 | $60.88M | $-17.14M | 97.28% | -22.00% | -28.16% |
| 2022 | $23.90M | $-18.74M | 86.23% | -120.98% | -78.40% |
| 2023 | $2.24M | $-42.19M | -67.26% | -1,700.54% | -1,884.50% |
| 2024 | $1.32M | $-34.11M | -262.41% | -3,244.87% | -2,579.03% |
| 2025 | $0.00 | $13.27M | — | — | — |